+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hepatocellular Carcinoma Treatment Market 2021-2025- Product Image
Global Hepatocellular Carcinoma Treatment Market 2021-2025- Product Image

Global Hepatocellular Carcinoma Treatment Market 2021-2025

  • ID: 5130930
  • Report
  • February 2021
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Hepatocellular Carcinoma Drugs Market 2021-2025

The publisher has been monitoring the hepatocellular carcinoma drugs market and it is poised to grow by $106.48 million during 2021-2025, progressing at a 4.10% during the forecast period. The report on hepatocellular carcinoma drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of liver diseases and lifestyle diseases and growing prevalence of lifestyle diseases. In addition, growing prevalence of lifestyle diseases is anticipated to boost the growth of the market as well.

The hepatocellular carcinoma drugs market analysis includes the therapy segment and geographic landscape.

The hepatocellular carcinoma drugs market is segmented as below:

By Therapy
  • Chemotherapy
  • Brachytherapy
  • Ablation therapy
By Geographical Landscapes
  • North America
  • Europe
  • APAC
  • ROW
This study identifies the increasing product launches as one of the prime reasons driving the hepatocellular carcinoma drug market growth during the next few years.

Thereport on hepatocellular carcinoma drugs market covers the following areas:
  • Hepatocellular carcinoma drugs market sizing
  • Hepatocellular carcinoma drugs market forecast
  • Hepatocellular carcinoma drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatocellular carcinoma drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, and Pfizer Inc. Also, the hepatocellular carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Therapy
  • Market segments
  • Comparison by Therapy
  • Chemotherapy - Market size and forecast 2019-2024
  • Brachytherapy - Market size and forecast 2019-2024
  • Ablation therapy - Market size and forecast 2019-2024
  • Market opportunity by Therapy
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Pfizer Inc.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Other1 - Market share 2020-2025 (%)
  • Comparison by Other1
  • Chemotherapy - Market size and forecast 2020-2025 ($ million)
  • Chemotherapy - Year-over-year growth 2020-2025 (%)
  • Brachytherapy - Market size and forecast 2020-2025 ($ million)
  • Brachytherapy - Year-over-year growth 2020-2025 (%)
  • Ablation therapy - Market size and forecast 2020-2025 ($ million)
  • Ablation therapy - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Other1
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Key customers
  • AbbVie Inc. - Segment focus
  • Amgen Inc. - Overview
  • Amgen Inc. - Business segments
  • Amgen Inc. - Key offerings
  • Amgen Inc. - Key customers
  • Amgen Inc. - Segment focus
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product and service
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Key customers
  • AstraZeneca Plc - Segment focus
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Key customers
  • Bayer AG - Segment focus
  • Bristol-Myers Squibb Co. - Overview
  • Bristol-Myers Squibb Co. - Product and service
  • Bristol-Myers Squibb Co. - Key offerings
  • Bristol-Myers Squibb Co. - Key customers
  • Bristol-Myers Squibb Co. - Segment focus
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Business segments
  • Eli Lilly and Co. - Key offerings
  • Eli Lilly and Co. - Key customers
  • Eli Lilly and Co. - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Product and service
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Key customers
  • Gilead Sciences Inc. - Segment focus
  • Johnson & Johnson - Overview
  • Johnson & Johnson - Business segments
  • Johnson & Johnson - Key offerings
  • Johnson & Johnson - Key customers
  • Johnson & Johnson - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
The publisher recognizes the following companies as the key players in the global hepatocellular carcinoma drugs market: AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing product launches.'

According to the report, one of the major drivers for this market is the increasing prevalence of liver diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Pfizer Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll